IQVIA (NYSE:IQV) Stock Rating Upgraded by Wall Street Zen

IQVIA (NYSE:IQV) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

A number of other brokerages have also recently issued reports on IQV. Citigroup lowered their target price on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Robert W. Baird set a $258.00 price objective on IQVIA and gave the company an “outperform” rating in a research note on Wednesday, October 29th. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. Morgan Stanley set a $240.00 target price on shares of IQVIA in a research note on Wednesday, February 11th. Finally, BMO Capital Markets set a $250.00 target price on shares of IQVIA in a research note on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $235.20.

IQVIA Stock Down 2.2%

IQV opened at $165.63 on Friday. IQVIA has a twelve month low of $134.65 and a twelve month high of $247.04. The company has a quick ratio of 0.70, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. The company’s 50-day moving average price is $217.61 and its two-hundred day moving average price is $208.27. The stock has a market cap of $28.11 billion, a price-to-earnings ratio of 21.07, a PEG ratio of 1.63 and a beta of 1.37.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. During the same period last year, the business posted $3.12 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities analysts expect that IQVIA will post 10.84 earnings per share for the current year.

Hedge Funds Weigh In On IQVIA

Large investors have recently modified their holdings of the stock. Eubel Brady & Suttman Asset Management Inc. purchased a new stake in shares of IQVIA in the 3rd quarter worth $14,278,000. OPTIMAS CAPITAL Ltd bought a new stake in shares of IQVIA in the third quarter valued at about $4,008,000. Eagle Rock Investment Company LLC lifted its stake in IQVIA by 33.6% in the third quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock worth $8,800,000 after acquiring an additional 11,657 shares during the period. Amundi grew its holdings in IQVIA by 46.3% during the 2nd quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock worth $210,722,000 after acquiring an additional 405,250 shares in the last quarter. Finally, Diversified Trust Co increased its position in IQVIA by 57.2% during the 3rd quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock valued at $8,087,000 after purchasing an additional 15,487 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.